| Nucleic Acids Research | Pages |
4[prime]-Acylated thymidine 5[prime]-triphosphates: a tool to increase selectivity towards HIV-1 reverse transcriptase
Introduction
Materials And Methods
Materials
Enzyme reaction buffers
DNA primer extension on 16S rRNA template
DNA primer extension on a DNA template
Results
DNA primer extension on RNA template catalyzed by HIV-1 RT
DNA primer extension on DNA template catalyzed by HIV-1 RT
DNA primer extension catalyzed by cellular DNA pols
Discussion
Acknowledgements
References
4[prime]-Acylated thymidine 5[prime]-triphosphates: a tool to increase selectivity towards HIV-1 reverse transcriptase
ABSTRACT 4[prime]-Acylated thymidines represent a new class of DNA chain terminators, since they have been shown to act as post-incorporation chain-terminating nucleotides despite the presence of a free 3[prime]-hydroxyl group. Here, we describe the action of the 4[prime]-acetyl- (MeTTP) and 4[prime]-propanoylthymidine 5[prime]-triphosphate (EtTTP) on HIV-1 reverse transcriptase in RNA- and DNA-dependent DNA synthesis and on DNA synthesis catalyzed by the cellular DNA polymerases [alpha], [beta], [delta] and [epsis]. MeTTP exhibits a high selectivity towards HIV-1 reverse transcriptase. By the use of the bulkier propanoyl group as the 4[prime]-substituent of the nucleoside 5[prime]-triphosphate, selectivity towards HIV-1 reverse transcriptase could be increased without affecting substrate efficiency. Thus, 4[prime]-modifications may serve as a tool to increase selectivity towards HIV-1 reverse transcriptase.
INTRODUCTION
DNA chain-terminating nucleoside analogs have found wide application in DNA sequencing techniques and antiviral chemotherapy. A common feature of chain-terminating nucleotides used in DNA sequencing procedures is lack of a 3[prime]-hydroxyl functionality on the 2[prime]-deoxyribose, such as in 2[prime],3[prime]-dideoxyribonucleotides or in 7-deaza-2[prime],3[prime]-deoxyguanosine (1,2). In antiviral chemotherapy to combat human immunodeficiency virus (HIV) infection, inhibition of reverse transcription catalyzed by HIV-1 reverse transcriptase (RT) is the mode of action of clinically approved nucleoside drugs. Chain termination is believed to be the primary mechanism by which the corresponding antiviral nucleoside analog 5[prime]-triphosphates exert their anti-HIV activities. A common structural feature of these nucleoside analogs is either lack of a 3[prime]-hydroxyl functionality as found in the 2[prime],3[prime]-dideoxyribonucleosides [like ddI, ddC or 2[prime],3[prime]-didehydro-2[prime],3[prime]-dideoxyribonucleosides (e.g. D4T)] or its substitution by another functionality [like 3[prime]-azidothymidine (AZT)] (3-10). Nucleoside 5[prime]-triphosphates with other modifications at the 2[prime]-deoxyribose moiety as well as a free 3[prime]-hydroxyl group are known to be substrates for DNA polymerases (DNA pols) and also RTs. Incorporation of these nucleotide analogs, which include 4[prime]-azidothymidine 5[prime]-triphosphate (11), arabinofuranosyl nucleotides [like araC (cytarabine) and F-ara-A (fludarabine)] (12,13) and 2[prime],2[prime]-difluorodeoxycytidine (gemcitabine) (14), do not lead to DNA chain termination, whereas inhibitors lacking the 3[prime]-hydroxyl functionality do. Inhibition of reverse transcription is believed to proceed via a pseudo-chain-termination mechanism (11-14). The aim in the design of new antiviral nucleosides is to develop tools which lead to high selectivity towards the targeted enzyme.
Recently, we have shown that the 4[prime]-acylated thymidines 4[prime]-acetylthymidine 5[prime]-triphosphate (MeTTP) and 4[prime]-propanoylthymidine 5[prime]-triphosphate (EtTTP) (for structures see Fig.
They represent a new class of DNA chain-terminating nucleotides even though they have a free 3[prime]-hydroxyl group. We have found that the 4[prime]-modification is an excellent tool to increase selectivity towards HIV-1 RT. In the present study, we describe the action of the 4[prime]-acylated thymidines MeTTP and EtTTP on HIV-1 RT in RNA- and DNA-dependent DNA synthesis and on DNA synthesis catalyzed by the cellular DNA pols [alpha], [beta], [delta] and [epsis]. Both thymidine analogs were used as substrates by HIV-1 RT with similar efficiency. DNA pol [alpha] was able to use the methylketone MeTTP as a substrate, whereas the ethylketone EtTTP was not a substrate for DNA pol [alpha]. None of the other cellular DNA pols present in the nucleus (DNA pol [beta], [delta] and [epsis]) were able to use the 4[prime]-modified thymidine analogs. Thus, selectivity towards HIV-1 RT could be enlarged by changing the size of the 4[prime]-substituent without affecting the substrate efficiency of the nucleotide for the lentiviral enzyme. These observations may be exploited to develop strategies for the design of new nucleosidic antiviral chemotherapeutics with higher selectivity.
MATERIALS AND METHODS
Materials
Figure 1. Structures of the 4[prime]-acylated thymidine 5[prime]-triphosphates MeTTP and EtTTP. MeTTP and EtTTP were synthesized according to the procedure described previously (15,17). Standard nucleotides and Escherichia coli 16S and 23S rRNA were purchased from Boehringer Mannheim. DNA oligonucleotides were prepared with a solid phase DNA synthesizer (Applied Biosystems) from [beta]-cyanoethyl-protected phosphoramidites, purified by the `trityl-on' procedure, deprotected and purified by HPLC and PAGE. DNA primers were labeled at the 5[prime]-end with [[gamma]-32P]ATP (5000 Ci/mmol; Amersham) and T4 polynucleotide kinase (New England Biolabs) (2). Human DNA pol [beta] was purchased from Chimerx. HIV-1 RT was purified as described (18). Calf thymus DNA pols [alpha], [delta] and [epsis] were purified according to published procedures (19-21). Proliferating cell nuclear antigen (PCNA) was overexpressed and purified as described (22). One unit of DNA pol activity corresponds to incorporation of 1 nmol 2[prime]-deoxyribonucleoside monophosphate into acid-precipitable material in 60 min at 37°C.
Enzyme reaction buffers
Buffer A: 20 mM Tris-HCl, pH 7.5, 6 mM MgCl2, 40 mM KCl, 0.5 mM DTT. Buffer B: 20 mM K2HPO4/KH2PO4, pH 7.2, 10 mM MgCl2, 0.5 mM DTT, 1.25 mg/ml BSA. Buffer C: 50 mM Tris-HCl, pH 8.7, 10 mM MgCl2, 10 mM KCl, 1 mM DTT. Buffer D: 50 mM Tris-HCl, pH 6.5, 5 mM MgCl2, 0.5 mM DTT, 1.25 mg/ml BSA.
DNA primer extension on 16S rRNA template
The 5[prime]-end-labeled 20 base oligonucleotide primer was annealed to its complementary site on E.coli 16S rRNA (positions 116-135 using the deoxyribonucleotide numbering system of 23) by heating the DNA primer and a mixture of 16S and 23S rRNA to 80°C for 5 min and subsequent cooling to 25°C within 1 h.
(5[prime]) d(32P-GCAGTTTCCCAGACATTACT)
(3[prime]) r(...CGUCAAAGGGUCUGUAAUGAGUGGGCAGGCGG...)
| |
20 27
Each DNA primer extension reaction mixture (10 µl) contained, dissolved in buffer A, 73 fmol labeled 20 base DNA primer, 0.5 µg E.coli 16S/23S rRNA mixture and 10 µM each dATP, dGTP and dCTP and various concentrations of TTP, MeTTP or EtTTP as indicated in the figure legends. The reactions were initiated by addition of 0.3 U HIV-1 RT and incubated for 15 min at 37°C and analyzed in an 11% polyacrylamide denaturating sequencing gel (National Diagnostics). After electrophoresis the gel was transferred to filter paper (Whatmann 3MM) and dried at 80°C. The radioactivity in the DNA bands was quantified using a PhosphorImager (Molecular Dynamics). The relative velocities of incorporation of MeTTP and EtTTP were determined by dividing the radioactivity in the first T site (position 27) by radioactivity of the band 1 nt shorter (position 26), as previously described (8,9,24). The Km and Vmax values were then calculated from the Michaelis-Menten equation.
DNA primer extension on a DNA template
The 5[prime]-end-labeled 20 base oligonucleotide primer was annealed to its complementary site on a 40 base oligonucleotide as described above.
(5[prime]) d(32P-GTGGTGCGAATTCTGTGGAT
(3[prime]) d(CACCACGCTTAAGACACCTAGTCGTTCCTACTTGCTGGCT)
| |
20 30
DNA primer extension reactions with HIV-1 RT contained, in a final volume of 10 µl in buffer A, 73 fmol labeled 20 base DNA primer, 230 fmol 40 base DNA template and 10 µM each dATP, dGTP and dCTP, various concentrations of TTP, MeTTP or EtTTP as indicated in the figure legends and 0.05 U HIV-1 RT. Incubation was performed for 15 min at 37°C and analyzed and quantified as described above. DNA primer extension reactions with DNA pols [alpha] and [beta] were performed in buffers B and C respectively and 0.1 U enzyme was used. When DNA pol [delta] was used to perform DNA primer extension each reaction mixture (20 µl) contained, in buffer D, 36 fmol labeled 20 base DNA primer, 54 fmol 40 base DNA template, 90 ng PCNA and 20 µM each dATP, dGTP and dCTP, various concentrations of TTP, MeTTP or EtTTP as indicated in the figure legends and 0.01 U DNA pol [delta]. Incubation was performed for 15 min at 37°C and the products were analyzed and quantified as described above. When DNA pol [epsis] was used to catalyze DNA synthesis the reaction mixtures (20 µl) contained, in buffer D, 36 fmol labeled 20 base DNA primer, 54 fmol 40 base DNA template and 30 µM each dATP, dGTP and dCTP and various concentrations of TTP, MeTTP or EtTTP as indicated in the figure legends. The reactions were initiated by addition of 0.4 U DNA pol [epsis], incubated for 15 min at 37°C and the products analyzed and quantified as described above.
RESULTS
DNA primer extension on RNA template catalyzed by HIV-1 RT
The action of the 4[prime]-acylated thymidine 5[prime]-triphosphates MeTTP and EtTTP (for structures see Fig.
Figure 2. Incorporation of MeTTP and EtTTP into DNA by HIV-1 RT using rRNA template. The numbers on the left side of the figure indicate the length of oligonucleotide synthesized in primer extension. Lane 1, HIV-1 RT incubated with 10 µM each dATP, dCTP and dGTP and 32P-labeled 20 base DNA primer annealed to 16S rRNA; lanes 2-8, as lane 1 but with 1, 6, 10, 15, 20, 50 and 100 µM MeTTP respectively; lanes 9-15, as lane 1 but with 1, 6, 10, 15, 20, 50 and 100 µM EtTTP respectively; lane 16, control reaction, as lane 1 but with 10 µM TTP. When increasing concentrations of either MeTTP or EtTTP (1-100 µM) were added to the reaction mixture a decrease in the amount of the 26 base product and an increase in the 27 base product was observed (Fig.
DNA primer extension on DNA template catalyzed by HIV-1 RT
Recently we showed that DNA-directed incorporation of MeTTP by HIV-1 RT can result in a slower further elongation at the primer 3[prime]-terminus when a high enzyme:DNA substrate ratio was employed (15,16). However, to quantitate nucleotide insertion kinetics the enzyme has to be saturated with its DNA substrate and therefore low enzyme:DNA substrate ratios have to be employed (8-10,24). Under these conditions, MeTTP acted as a post-incorporation DNA chain terminator in DNA-dependent DNA synthesis catalyzed by HIV-1 RT (Fig.
Figure 3. Incorporation of MeTTP and EtTTP into DNA by HIV-1 RT using DNA template. The numbers on the left side of the figure indicate the length of oligonucleotide synthesized in primer extension. LM, line marker. Lane 1, HIV-1 RT incubated with 10 µM each dATP, dCTP and dGTP and 32P-labeled 20 base DNA primer annealed to 40 base DNA template; lanes 2-10, as lane 1 but with 1, 6, 10, 15, 20, 50, 100, 150 and 200 µM MeTTP respectively; lanes 11-19, as lane 1 but with 1, 6, 10, 15, 20, 50, 100, 150 and 200 µM EtTTP respectively; lane 20, control reaction, as lane 1 but with 10 µM TTP. The formation of longer reaction products indicated that some non-complementary dNTP molecules were incorporated into the first T site and subsequently the DNA primer strand was further elongated. This misincorporation tendency of HIV-1 RT confirms its known error-prone properties (25-28). When HIV-1 RT catalyzed primer extension in the presence of increasing concentrations of the 4[prime]-acylated thymidine analog MeTTP or EtTTP (1-200 µM), increasing incorporation was observed by accumulation of 30 base reaction products (Fig. Table 1.
Enzyme
Analog
16S rRNA template
40 base DNA template
Km (µM)
Vmax
Vmax/Km (per µM)
Km (µM)
Vmax
Vmax/Km (per µM)
HIV-1 RT
MeTTP
15
2.9
0.19
10
1.6
0.16
EtTTP
42
5.6
0.13
12
2.4
0.20
DNA pol [alpha]
MeTTP
n.a.
n.a.
n.a.
338
0.72
0.002
DNA primer extension catalyzed by cellular DNA pols
To evaluate the action of the 4[prime]-acylated thymidines MeTTP and EtTTP on cellular DNA pols we used the DNA primer/template complex described above. When DNA pol [alpha] was used to perform primer elongation in the presence of dATP, dGTP and dCTP, formation of a 29 base DNA product as major reaction product was observed (Fig.
Figure 4. Action of MeTTP and EtTTP on DNA pol [alpha]. The numbers on the left side of the figure indicate the length of oligonucleotide synthesized in primer extension. LM, line marker. Lane 1, DNA pol [alpha] incubated with 10 µM each dATP, dCTP and dGTP and 32P-labeled 20 base DNA primer annealed to 40 base DNA template; lanes 2-5, as lane 1 but with 50, 100, 150 and 200 µM MeTTP respectively; lanes 6-9, as lane 1 but with 50, 100, 150 and 200 µM EtTTP respectively; lane 10, control reaction, as lane 1 but with 10 µM TTP. Only trace amounts of misincorporation were observed in this case. In the presence of increasing concentrations of MeTTP (50-200 µM) DNA pol [alpha] incorporated this analog into the nascent DNA strand (Fig. Figure 5. Action of MeTTP and EtTTP on DNA pols [beta], [delta] and [epsis]. (Left) LM, line marker. Lane 1, DNA pol [beta] incubated with 10 µM each dATP, dCTP and dGTP and 32P-labeled 20 base DNA primer annealed to 40 base DNA template; lanes 2-5, as lane 1 but with 50, 100, 150 and 200 µM MeTTP respectively; lanes 6-9, as lane 1 but with 50, 100, 150 and 200 µM EtTTP respectively; lane 10, control reaction, as lane 1 but with 10 µM TTP. (Center) LM, line marker. Lane 1, DNA pol [delta] incubated with 20 µM each dATP, dCTP and dGTP, PCNA and 32P-labeled 20 base DNA primer annealed to 40 base DNA template; lanes 2-4, as lane 1 but with 100, 150 and 200 µM MeTTP respectively; lanes 5-7, as lane 1 but with 100, 150 and 200 µM EtTTP respectively; lane 8, control reaction, as lane 1 but with 10 µM TTP.(Right) As in the left panel but with DNA pol [epsis]. In spite of the fact that the 4[prime]-acylated thymidines MeTTP and EtTTP bear a free 3[prime]-hydroxyl group, this study indicates that their incorporation into DNA blocks further DNA chain elongation. DNA pols are thought to catalyze DNA polymerization by sequential conformational changes in the enzyme structure (29-31). HIV-1 RT is thought to undergo a conformational change after binding the nucleoside 5[prime]-triphosphate, which positions the nucleotide for phosphodiester bond formation (31). Therefore, the binding affinity of the nucleotide substrate at the active site in the RT is crucial for incorporation. The Km value represents a parameter for the binding affinity of the nucleotide at the active site (24). From the Km values the differences in the free binding energies of MeTTP and EtTTP can be calculated (24). It turned out that the free binding energy of MeTTP for HIV-1 RT in reverse transcription is ~0.6 kcal/mol higher than for EtTTP. This may be due to the bulkier 4[prime]-substituent, which may interfere with the enzyme or fix the sugar pucker conformation unfavorably for binding. However, the Km values for DNA-directed DNA synthesis with MeTTP and EtTTP are about the same. The substrate efficiency of both substrates was found to be about the same for both reactions. These studies revealed that an increase in the size of the 4[prime]-substituent by one methylene moiety did not have a significant effect on nucleotide binding and incorporation. In contrast, as shown recently (15,16), HIV-1 RT is able to promote chain elongation after incorporation of the methylketone MeTTP when high enzyme quantities are used. The ethylketone EtTTP acts as a chain-terminating nucleotide upon incorporation. Thus, the size of the 4[prime]-modification is less crucial for incorporation of the nucleotide by HIV-1 RT than for post-incorporation DNA elongation. The Km values obtained for incorporation of MeTTP and EtTTP are about the same and up to 50-fold greater than reported for TTP or antiviral nucleoside 5[prime]-triphosphates such as ddTTP, AZTTP and D4TTP elucidated in similar assays (8,9). It should be emphasized that the kinetic values for incorporation of normal nucleotides is dependent on the sequence under evaluation (31). Therefore, a direct comparison of the kinetic values should be done with caution. In treatment of antiviral diseases, the nucleosidic drugs are applied as nucleosides and have to be transformed into the corresponding 5[prime]-triphosphates by cellular kinases to be effective drugs. For further evaluation, the action of 4[prime]-acylated thymidines on cellular kinases has to be studied. As mentioned, selectivity towards a targeted enzyme is desirable in the design of new therapeutic agents. Therefore, we evaluated the action of MeTTP and EtTTP on four DNA pols (for reviews see 32-34) which are essential in cellular DNA replication (DNA pols [alpha], [delta] and [epsis]), in DNA repair processes (DNA pols [beta], [delta] and [epsis]), in repair recombination (DNA pol [epsis]; 35) and in V(D)J recombination (DNA pol [delta]; 36). It turned out that the 4[prime]-acylated thymidine analogs were very poor substrates for all cellular DNA pols tested. Only DNA pol [alpha] was able to incorporate MeTTP, at ~100-fold less substrate efficiency than that obtained for HIV-1 RT. The bulkier EtTTP was not incorporated by DNA pol [alpha]. DNA pols [beta], [delta] and [epsis] incorporated neither MeTTP nor EtTTP. Thus, an increase in size of the 4[prime]-modification ensures that the thymidine analog EtTTP is not a substrate for incorporation by any cellular nuclear DNA pol. Since this structural modification does not change the sugar pucker conformation (17), the different reactivity of EtTTP to MeTTP can be ascribed to the increased bulk of the 4[prime]-substituent. Our studies demonstrate that the 4[prime]-acylated thymidine analogs MeTTP and EtTTP are preferentially incorporated into DNA by HIV-1 RT. To assess the influence of the 4[prime]-acyl modification on DNA synthesis catalyzed by HIV-1 RT and cellular DNA pols the size of the sugar pucker substituent was increased. Enlargement of the 4[prime]-methylketone MeTTP by one methylene moiety to the 4[prime]-ethylketone EtTTP resulted in rejection of the thymidine analog as a substrate for cellular nuclear DNA pols, without reducing its substrate efficiency for HIV-1 RT in comparison with MeTTP. Thus, the 4[prime]-modification may serve as a tool to increase selectivity towards the lentiviral enzyme. These observations make 4[prime]-modified nucleotides very interesting in the search for new nucleosidic drugs. Additionally, it would be quite significant if this strategy could also be applied to other positions of the sugar residue of nucleotides. Investigations along these lines are in progress. This work was supported by the Swiss National Science Foundation and Novartis AG.
DISCUSSION
ACKNOWLEDGEMENTS
REFERENCES
This article has been cited by other articles:
This page is run by Oxford University Press, Great Clarendon Street, Oxford OX2 6DP, as part of the OUP Journals
Comments and feedback: www-admin{at}oup.co.uk
Last modification: 14 Aug 1998
Copyright©Oxford University Press, 1998.
![]()
CiteULike
Connotea
Del.icio.us What's this?
![]()
![]()

![]()
![]()
![]()
B. A. Mulder, S. Anaya, P. Yu, K. W. Lee, A. Nguyen, J. Murphy, R. Willson, J. M. Briggs, X. Gao, and S. H. Hardin
Nucleotide modification at the {gamma}-phosphate leads to the improved fidelity of HIV-1 reverse transcriptase
Nucleic Acids Res.,
September 1, 2005;
33(15):
4865 - 4873.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
V. Kempeneers, M. Renders, M. Froeyen, and P. Herdewijn
Investigation of the DNA-dependent cyclohexenyl nucleic acid polymerization and the cyclohexenyl nucleic acid-dependent DNA polymerization
Nucleic Acids Res.,
July 12, 2005;
33(12):
3828 - 3836.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
K. Vastmans, M. Froeyen, L. Kerremans, S. Pochet, and P. Herdewijn
Reverse transcriptase incorporation of 1,5-anhydrohexitol nucleotides
Nucleic Acids Res.,
August 1, 2001;
29(15):
3154 - 3163.
[Abstract]
[Full Text]
[PDF]
![]()
This Article ![]()
![]()
Abstract
![]()
Print PDF (116K)
![]()
Alert me when this article is cited
![]()
Alert me if a correction is posted
![]()
Services ![]()
![]()
Email this article to a friend
![]()
Similar articles in this journal
![]()
Similar articles in ISI Web of Science
![]()
Similar articles in PubMed
![]()
Alert me to new issues of the journal
![]()
Add to My Personal Archive
![]()
Download to citation manager
![]()
Search for citing articles in:
ISI Web of Science (8)
![]()
Request Permissions ![]()
Commercial Re-use Guidelines
for Open Access NAR Content
![]()
Google Scholar ![]()
![]()
Articles by Marx, A.
![]()
Articles by Giese, B.
![]()
Search for Related Content
![]()
PubMed ![]()
![]()
PubMed Citation
![]()
Articles by Marx, A.
![]()
Articles by Giese, B.
![]()
Social Bookmarking ![]()
![]()
What's this?